Novo Crashes After Obesity Drug Misses Lofty Expectations. Lilly, Viking And Amgen Surge.

Autor:	GATLIN, ALLISON (AUTHOR), CARSON, ED (AUTHOR)
Předmět:	NOVO Nordisk A/S, QUARTERLY reports, GLUCAGON-like peptide 1, PATIENT compliance, TYPE 2 diabetes, STOCKS (Finance), MEDICATION therapy management, PEOPLE with diabetes
Zdroj:	Investors Business Daily. 12/20/2024, pN.PAG-N.PAG. 1p.
Abstrakt:	Novo Nordisk's stock plummeted after its new weight-loss drug, CagriSema, fell short of expectations in a study on patients with obesity. While patients lost 22.7% of their body weight over 68 weeks, missing the company's guidance of 25% weight loss raised safety concerns. Competitors like Eli Lilly and Viking Therapeutics saw their stocks rise, with ongoing developments in the weight-loss drug market impacting the broader landscape of diabetes management devices. [Extracted from the article]
Databáze:	Regional Business News
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.